Question 11 out of 1 pointsRefer to Hervieu et al. (2020) for Questions #1-5.Question #1: In figure 1, M1268T refers to:Selected Answer: A. a constitutively active MET mutantAnswers:A. a constitutively active MET mutantB. Wild type non-cancerous murine modelC. a constitutively active mTOR mutantD. a naturally occurring non-cancerous tyrosine kinase Question 21 out of 1 pointsBy inspection of the Western Blots shown in Figure 1D, the absence of a P-AKT band with MET inhibition in mutant cells suggests that:Selected Answer: C. Mutant MET activates AKT.Answers: A. Mutant MET inactivates AKT.B. MET is downstream of AKT.C. Mutant MET activates AKT.D. The relative amounts of P-AKT are comparable in DMSO and LY treated samples from mutant MET cells. Question 31 out of 1 pointsBy inspection of the Western Blots shown in Figure 3 Panels C and D, why did the authors decide to probe for tubulin?Selected Answer: A. To show that all samples were loaded equally.Answers:A. To show that all samples were loaded equally.B. To show the involvement of tubulin in the MET-PI3K-AKT pathway.C.To verify that p70-S6K is indeed upstream of mTOR.D. To prove that there are proteins that are not effected by DMSO treatment. Question 41 out of 1 pointsIn Figure 4,